Neoplasms, Breast Clinical Trial
Official title:
Study of Cancer Stem Cell Vcccinie That as a Specific Antigen in Metastatic Adenocarcinoma of the Breast
Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically distinctmurine tumors after their inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.
To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the
investigators will harvest peripheral blood and tumor specimen from patients with Breast
Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the
Breast Cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow
tumor cells from the tumor specimen of the Breast Cancer patient using a similar protocol as
investigators reported .
Aim 1: To demonstrate, in vitro, the relative cellular anti-Breast Cancer CSC immunity
induced by Breast Cancer CSC-DC primed cytotoxic T cells.
Aim 2: To determine, in vitro, specific binding and lysis of Breast Cancer CSCs by
antibodies produced by purified B cells from PBMCs stimulated with Breast Cancer CSC-DC.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00251433 -
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT01271738 -
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
|
N/A | |
| Recruiting |
NCT04892342 -
Study of ESG401 in Adults With Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02213042 -
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT01137994 -
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00790816 -
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
|
Phase 1 | |
| Completed |
NCT00051103 -
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
|
Phase 2 | |
| Completed |
NCT00320411 -
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00258050 -
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
|
Phase 1 | |
| Terminated |
NCT01498588 -
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
|
Phase 2 | |
| Terminated |
NCT00479856 -
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
|
Phase 2 | |
| Completed |
NCT00320385 -
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT00062686 -
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00996762 -
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
|
Phase 1 | |
| Terminated |
NCT02913729 -
Pre- Versus Postoperative Accelerated Partial Breast Irradiation
|
N/A | |
| Completed |
NCT01160211 -
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
| Completed |
NCT01815294 -
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
|
Phase 1 | |
| Terminated |
NCT00437073 -
Brain Metastases In ErbB2-Positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT00356811 -
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
|
Phase 2 |